|
 |
|||||||||||||||||||
|
|||||||||||||||||||
|
|||||||||||||||||||
 |
 |
|
|
a Vanderbilt Center for Bone Biology, Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA b OsteoScreen, San Antonio, Texas, USA c Center for Clinical and Basic Research, Ballerup, Denmark d Neosil Inc., Emeryville, California, USA
Key Words: bone morphogenetic protein • hair follicle • bone formation • anagen • proteasome inhibitors
Address for correspondence: Gregory R. Mundy, M.D., Vanderbilt Center for Bone Biology, 1235 MRB IV, Nashville, TN 37232-0575. Voice: 615-322-6110; fax: 615-343-2611. gregory.r.mundy{at}vanderbilt.edu
We propose that the remodeling process that occurs in localized areas on endosteal bone surfaces and in Haversian canals shares many features in common with the mammalian hair cycle. In both, there are phases of resorption or regeneration, a transition phase, and then a phase of growth, termed anagen in the hair follicle, and formation in the bone remodeling cycle. Furthermore, we suggest that these processes both use the same molecular mechanisms, and specifically the Hedgehog–BMP–Wnt signal transduction cascades. We have found that proteasome inhibitors, which enhance bone formation by effects on these cascades, also stimulate anagen induction and hair growth in the murine and human hair follicle, and propose they do so by effects on similar or identical molecular targets.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
